Longeveron Presents at Second Euro-Geroscience Conference

Longeveron management presents live at the Second Euro-Geroscience Conference and at a pre-meeting task force

MIAMI, March 24, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management presented at the Second Euro-Geroscience Conference, being held from March 24-25, 2022 virtually and in Toulouse, France, and at a pre-meeting task force.

The details of Longeveron’s presentations are as follows:

  • Session: Euro-Geroscience Task Force: “Challenges in Developing Geroscience Drug Trials”
    Format: Oral presentation: “Targeting Frailty with Stem Cells,” presented by Anthony Oliva, Ph.D. Senior Scientist
    Date: Wednesday, March 23, 2022
    Time: 10:30 – 10:50 am CET
  • Session: Session 6: “Designing Clinical Trials in Geroscience”
    Format: Oral Presentation: “OC23 – Lomecel-B as a Geroscience Therapeutic Candidate: Clinical Trial Results” presented by Anthony Oliva, Ph.D. Senior Scientist
    Date: Friday, March 25, 2022
    Time: 4:50 pm CET

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.

Brendan Payne
Stern Investor Relations
Tel: (212) 362-1200
Email: Brendan.payne@sternir.com

Source: Longeveron


error: Content is protected !!